<DOC>
	<DOCNO>NCT01156961</DOCNO>
	<brief_summary>This single arm , open label study assess safety profile Avastin ( bevacizumab ) combination paclitaxel first-line treatment patient locally recurrent metastatic Her2-negative breast cancer . Patients receive Avastin , either 10 mg/kg intravenously ( iv ) every 2 week 15 mg/kg iv every 3 week . Correspondingly , paclitaxel administer dose 90 mg/m2 day 1 , 8 15 every 28-day cycle 175 mg/m2 day 1 every 21-day cycle . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study The Safety Profile First-line Avastin ( Bevacizumab ) Combination With Paclitaxel Patients With Locally Recurrent Metastatic Her2-negative Breast Cancer ( AVATAX )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally recurrent metastatic Her2negative breast cancer Locally recurrent disease must amenable radiation therapy resection curative intent Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Prior Adjuvant chemotherapy allow ; taxanebased diseasefree interval completion &gt; /=12 month require Adequate haematological , renal liver function Previous chemotherapy locally recurrent metastatic disease Radiation therapy metastatic disease ( except relief metastatic bone pain irradiation &lt; /= 30 % marrowbearing bone ) CNS metastases Preexisting peripheral neuropathy Clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>